The MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE (MDC) is a member of the Helmholtz Association of National Research Centers, supported by the Federal Government of Germany and the Senate of Berlin. It is dedicated to interdisciplinary research in the areas of Cardiovascular and Metabolic Diseases, Cancer and Function of Dysfunction of the Nervous System. Additionally the MDC has launched a Systems Biology program, the Berlin Institute for Medical Systems Biology (BIMSB), to integrate systems approaches, 'omics'-technologies and computational focus and to address gene regulatory mechanisms and their role in health and disease.
For the Rajewsky lab "Systems Biology of Gene Regulatory Elements" and its newly established organoids platform we are seeking a highly motivated and hard working postdoctoral researcher with an expertise in genome editing. The successful candidate will work in close collaboration with the platform leader and will be responsible for:
- Designing target specific CRISPR/Cas9 tools
- Methods optimization for efficient gene editing
- Generation of knock-out and knock-in iPSC cell lines
- Correction of genetic mutation
- Validation of genome-edited iPSC cell lines
- Development of new protocols for the organoid field
- Writing reports, publications and grant applications
Self-motivated individuals with an advanced degree in any area of biomedical sciences and especially those with prior experience in iPSC/stem related research and in the engineering of mouse and human genomes using up-to-date technologies (CRISPR/Cas or TALEN) and bioinformatics are encouraged to apply.
The MDC is an equal opportunity employer and supports gender equality.
Please, send your application including all documents indicating the registration number preferably by e-mail to firstname.lastname@example.org as pdf files (2 files of 5 MB at the maximum) as we do not return any papers.
The position is funded according to the German TVÖD E13 (Bund) based on experience and qualification.
As soon as possible.
The initial contract will be offered for 2 years with the possibility of extension.
31 August 2019